reports

Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025

ASHEVILLE, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health, a healthcare company pioneering technology for medical products and services,…

3 weeks ago

Avicanna Reports Q3 2025

November 14, 2025 17:30 ET  | Source: Avicanna Inc. TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or…

4 weeks ago

Range Impact Reports 3Q 2025 Financial Results

Cleveland, Ohio, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public…

4 weeks ago

Akums Reports Q2 FY26 Results; Strengthens International Presence

Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second…

1 month ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…

1 month ago

Senores Pharma Reports Strong Q2 & H1 FY26 Performance, Sustains Growth Momentum Across Businesses

AHMEDABAD, India, Nov. 7, 2025 /PRNewswire/ -- Senores Pharmaceuticals Limited continued its strong growth trajectory in the second quarter of FY26,…

1 month ago

Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter…

1 month ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the…

1 month ago

Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa

DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…

1 month ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

1 month ago